Hospira announced the launch of Bivalirudin for Injection, the first generic version of The Medicines Company’s Angiomax.

Angiomax is an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. Angiomax is also indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin.

RELATED: Sandoz to Launch Generic Angiomax for Injection

Bivalirudin for Injection is available as a lyophilized powder in a 250mg/vial strength in single-use flip-top vials.

For more information call (800) 441-4100 or visit Hospira.com.